Tonix Pharmaceuticals Holding Corp shares rose 5.1% Wednesday after the company disclosed a coverage agreement with a group purchasing organization (GPO) that becomes effective May 1. The agreement grants coverage access to approximately 35 million U.S. commercial lives, a figure the company says represents about 20% of the roughly 177 million commercial lives in the United States.
The coverage under the GPO applies to TONMYA, Tonix's cyclobenzaprine HCl sublingual tablets approved to treat fibromyalgia in adults. TONMYA was launched commercially in November 2025 and, according to the company, is the first FDA-approved therapy for adult fibromyalgia in more than 15 years. The product is described as a first-in-class non-opioid analgesic intended for nightly administration as a long-term treatment.
In addition to the GPO agreement, Tonix reported progress with government programs. The company stated that TONMYA is covered under Medicaid in 38 states, representing coverage for about 55 million lives. The company quantified that 55 million lives as roughly 73% of the approximately 75 million Medicaid lives that it referenced. Tonix also said that discussions with Medicare and other Medicaid entities remain ongoing.
Context and implications
Tonix provided explicit coverage figures from both commercial and public insurance channels. The GPO agreement's effective date is May 1 and the company provided the exact population estimates for the commercial and Medicaid coverages. The product details given by the company include the active ingredient - cyclobenzaprine HCl - and the indicated use as a nightly, long-term, non-opioid analgesic for adults with fibromyalgia. The commercial launch date for TONMYA was listed as November 2025.
Summary points
- Tonix shares climbed 5.1% following announcement of a GPO coverage agreement effective May 1 that covers about 35 million commercial lives.
- TONMYA, a cyclobenzaprine HCl sublingual tablet for fibromyalgia, launched commercially in November 2025 and is described as the first FDA-approved fibromyalgia treatment for adults in more than 15 years.
- The drug is covered under Medicaid in 38 states, covering approximately 55 million lives, which the company says is about 73% of roughly 75 million Medicaid lives; talks with Medicare and other Medicaid programs are continuing.
Risks and uncertainties noted by the company
- Coverage under Medicare remains unresolved - the company stated that discussions are ongoing, indicating uncertainty about Medicare access.
- While Medicaid coverage exists in 38 states, coverage is not universal across all states, leaving potential variability in public-payer access by state.
- The commercial coverage through the GPO represents about 20% of the stated commercial lives - the company-reported figure highlights that a majority of commercial lives remain outside this specific agreement.
The company-provided figures and timelines are the basis for the stock movement reported. No additional outcomes or projections were provided in the company's statements.